Energesis Pharmaceuticals is a biopharmaceutical company organized around treatment of obesity, diabetes, and related metabolic diseases. The firm's novel approach addresses increasing the body's energy expenditure - specifically to target the expenditure rather than the intake side of the weight maintenance equation: targeting brown adipose tissue (BAT). The Companys approach is a novel strategy leveraging recent scientific insights in BAT biology to increase the bodys ability to burn stored fat and lower insulin resistance. Diabetes and its major underlying cause - obesity - have reached epidemic proportions in the U.S. and the rest of the industrialized world. With very few safe and effective non-invasive treatments for obesity available, and new approaches for diabetes needed, the firm's technology is designed to enable development of drugs that increase energy expenditure, a strategy for addressing both obesity and diabetes that is strongly supported by the scientific literature
